Collectively, these findings shed light on the pivotal contribution of VPS25 to HNSCC progression and immunosuppression, as well as its implications for clinical management, paving the way for targeted therapies and personalized medicine approaches. Here, VPS25 is linked to head and neck squamous cell carcinoma.